3/3
08:23 am
rnaz
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer
Neutral
Report
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer
3/3
08:01 am
rnaz
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer
Low
Report
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer
2/23
08:01 am
rnaz
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
Low
Report
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
2/5
08:46 am
rnaz
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 [Yahoo! Finance]
High
Report
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 [Yahoo! Finance]
2/5
08:04 am
rnaz
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
High
Report
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
1/24
05:10 am
rnaz
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/6
08:37 am
rnaz
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma [Yahoo! Finance]
Medium
Report
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma [Yahoo! Finance]
1/6
08:01 am
rnaz
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
Medium
Report
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma